从埃塞俄比亚输入的无并发症恶性疟原虫疟疾患者采用二氢青蒿素-哌喹治疗失败。
Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia.
机构信息
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena Rome 299, 00161, Rome, Italy.
出版信息
Infection. 2018 Dec;46(6):867-870. doi: 10.1007/s15010-018-1174-9. Epub 2018 Jul 6.
Abstract
Dihydroartemisinin-piperaquine (DHA-PPQ) is the artemisinin combination therapy that was recently introduced for the treatment of Plasmodium falciparum uncomplicated malaria, but emerging resistance in South-East Asia is threatening its use. This report describes a case of DHA-PPQ treatment failure in uncomplicated malaria occurring in an immigrant living in Italy, after a travel to Ethiopia. Thirty days after malaria recovery following DHA-PPQ therapy, the patient had malaria recrudescence. According to the genotyping analysis, the same P. falciparum was responsible for both episodes. Thus, it seems important to consider possible malaria recrudescence occurring after DHA-PPQ therapy in patients from African countries.
摘要
双氢青蒿素-哌喹（DHA-PPQ）是一种青蒿素类复方疗法，最近被引入用于治疗无并发症的恶性疟原虫疟疾，但在东南亚出现的抗药性正在威胁其使用。本报告描述了一例在意大利生活的移民在前往埃塞俄比亚旅行后，出现无并发症疟疾且 DHA-PPQ 治疗失败的病例。在 DHA-PPQ 治疗后 30 天，患者疟疾复发。根据基因分型分析，两次感染均由同一株恶性疟原虫引起。因此，对于来自非洲国家的患者，在 DHA-PPQ 治疗后，可能会出现疟疾复发，这一点似乎很重要。
相似文献
1
Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia.从埃塞俄比亚输入的无并发症恶性疟原虫疟疾患者采用二氢青蒿素-哌喹治疗失败。
Infection. 2018 Dec;46(6):867-870. doi: 10.1007/s15010-018-1174-9. Epub 2018 Jul 6.
2
Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia.双氢青蒿素-哌喹治疗一名来自埃塞俄比亚旅行者的非复杂性恶性疟原虫疟疾失败。
Malar J. 2016 Nov 3;15(1):525. doi: 10.1186/s12936-016-1572-3.
3
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.在埃塞俄比亚，青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗无并发症恶性疟原虫和氯喹与双氢青蒿素-哌喹治疗无并发症间日疟原虫感染的疗效。
Malar J. 2022 Dec 1;21(1):359. doi: 10.1186/s12936-022-04350-z.
4
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-甲氟喹治疗尼日尔马里无并发症恶性疟的疗效。
Malar J. 2018 Jan 25;17(1):52. doi: 10.1186/s12936-018-2200-1.
5
Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗巴布亚新几内亚无并发症疟疾的疗效。
Malar J. 2018 Oct 5;17(1):350. doi: 10.1186/s12936-018-2494-z.
6
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.双氢青蒿素哌喹治疗非复杂性恶性疟
Cochrane Database Syst Rev. 2014 Jan 20;2014(1):CD010927. doi: 10.1002/14651858.CD010927.
7
Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.中越地区二氢青蒿素/哌喹与青蒿琥酯单药治疗无并发症恶性疟原虫疟疾的疗效。
J Antimicrob Chemother. 2020 Aug 1;75(8):2272-2281. doi: 10.1093/jac/dkaa172.
8
High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia.青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗索马里无并发症恶性疟的高疗效。
Malar J. 2019 Jul 11;18(1):231. doi: 10.1186/s12936-019-2864-1.
9
Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan.在苏丹季节性传播不稳定地区，DHA-PPQ和蒿甲醚/苯芴醇对单纯性恶性疟患者的疗效。
Malar J. 2017 Apr 20;16(1):163. doi: 10.1186/s12936-017-1817-9.
10
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.双氢青蒿素-哌喹治疗越南耐多药恶性疟原虫疟疾：随机临床试验
Lancet. 2004 Jan 3;363(9402):18-22. doi: 10.1016/s0140-6736(03)15163-x.
引用本文的文献
1
Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola.安哥拉南部恶性疟原虫分离株中pfmdr1和pfpm2基因拷贝数变异的低流行率
Malar J. 2025 Jan 10;24(1):5. doi: 10.1186/s12936-024-05240-2.
2
Plant Extracts as a Source of Natural Products with Potential Antimalarial Effects: An Update from 2018 to 2022.植物提取物作为具有潜在抗疟作用的天然产物来源：2018年至2022年的最新情况
Pharmaceutics. 2023 Jun 1;15(6):1638. doi: 10.3390/pharmaceutics15061638.
3
Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis.在撒哈拉以南非洲地区，治疗无并发症恶性疟原虫疟疾的青蒿琥酯-咯萘啶、青蒿琥酯-阿莫地喹和双氢青蒿素-哌喹的疗效：系统评价和荟萃分析。
PLoS One. 2022 Mar 10;17(3):e0264339. doi: 10.1371/journal.pone.0264339. eCollection 2022.
4
Prevalence of Mutations in the Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against .该基因中突变的发生率及其与针对……的常见喹啉类药物体外敏感性的关联。
Pharmaceutics. 2021 Aug 17;13(8):1273. doi: 10.3390/pharmaceutics13081273.
5
Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy.抗疟药物耐药性及其对世界卫生组织全球技术战略的影响。
Curr Epidemiol Rep. 2021;8(2):46-62. doi: 10.1007/s40471-021-00266-5. Epub 2021 Mar 14.
6
Chemo Suppressive and Curative Potential of Against : Evidence for in vivo Antimalarial Activity.[药物名称]对[疾病名称]的化疗抑制和治愈潜力：体内抗疟活性证据
J Exp Pharmacol. 2020 Sep 7;12:313-323. doi: 10.2147/JEP.S262026. eCollection 2020.
7
No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China-Myanmar border.在中国-缅甸边境地区的青蒿素耐药疟疾流行地区，没有发现恶性疟原虫裂殖体蛋白 2 基因拷贝数扩增的证据。
Malar J. 2020 Sep 14;19(1):334. doi: 10.1186/s12936-020-03410-6.
8
K13-Mediated Reduced Susceptibility to Artemisinin in Plasmodium falciparum Is Overlaid on a Trait of Enhanced DNA Damage Repair.疟原虫中 K13 介导的对青蒿素敏感性降低与增强的 DNA 损伤修复特性重叠。
Cell Rep. 2020 Aug 4;32(5):107996. doi: 10.1016/j.celrep.2020.107996.
9
Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.恶性疟原虫氯喹耐药转运蛋白（PfCRT）基因突变的流行情况及其与非洲恶性疟原虫分离株体外常见抗疟药物敏感性的关系。
Malar J. 2020 Jun 5;19(1):201. doi: 10.1186/s12936-020-03281-x.
10
Targeted deep amplicon sequencing of kelch 13 and cytochrome b in Plasmodium falciparum isolates from an endemic African country using the Malaria Resistance Surveillance (MaRS) protocol.采用 Malaria Resistance Surveillance（MaRS）方案，对来自地方性非洲国家的恶性疟原虫分离株进行 Kelch13 和细胞色素 b 靶向深度扩增子测序。
Parasit Vectors. 2020 Mar 14;13(1):137. doi: 10.1186/s13071-020-4005-7.
本文引用的文献
1
Drug resistance in Plasmodium.疟原虫的耐药性。
Nat Rev Microbiol. 2018 Mar;16(3):156-170. doi: 10.1038/nrmicro.2017.161. Epub 2018 Jan 22.
2
Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.基于青蒿素的联合疗法在不同种族人群中治疗恶性疟的药代动力学考量
Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1115-1133. doi: 10.1080/17425255.2017.1391212. Epub 2017 Oct 20.
3
A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine.一种变异的疟原虫氯喹抗性转运蛋白（PfCRT）异构体可能导致对一线联合用药磷酸哌喹产生耐药性。
mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
4
Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan.在苏丹季节性传播不稳定地区，DHA-PPQ和蒿甲醚/苯芴醇对单纯性恶性疟患者的疗效。
Malar J. 2017 Apr 20;16(1):163. doi: 10.1186/s12936-017-1817-9.
5
Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa.非洲出现对青蒿素耐药的恶性疟原虫。
N Engl J Med. 2017 Mar 9;376(10):991-3. doi: 10.1056/NEJMc1612765. Epub 2017 Feb 22.
6
Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.恶性疟原虫对青蒿素衍生物和哌喹的耐药性：柬埔寨疟疾消除面临的重大挑战。
Am J Trop Med Hyg. 2016 Dec 7;95(6):1228-1238. doi: 10.4269/ajtmh.16-0234. Epub 2016 Oct 17.
7
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.耐哌喹恶性疟原虫疟疾的替代标志物：一项表型-基因型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):174-183. doi: 10.1016/S1473-3099(16)30415-7. Epub 2016 Nov 3.
8
Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia.双氢青蒿素-哌喹治疗一名来自埃塞俄比亚旅行者的非复杂性恶性疟原虫疟疾失败。
Malar J. 2016 Nov 3;15(1):525. doi: 10.1186/s12936-016-1572-3.
9
A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.恶性疟原虫K13螺旋桨多态性的全球地图。
N Engl J Med. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137.
10
Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.全球普遍存在的 PfMDR1 突变可调节恶性疟原虫对基于青蒿素的联合疗法的敏感性。
Nat Commun. 2016 May 18;7:11553. doi: 10.1038/ncomms11553.
Zotero 插件